MEI Pharma winds down cancer drug program outside Japan, shares slip

Kyowa Kirin

05/12/2022 22:59

** Shares of cancer drug developer MEI Pharma Inc  MEIP.O 
fall 35.5% to $0.26 after market
    ** Company and partner Kyowa Kirin  4151.T  discontinue
development of cancer drug zandelisib outside of Japan
 urn:newsml:reuters.com:*:nBw32gQr9a
    ** MEIP announces plans to start a staggered workforce cut
of about 30% in connection with winding down of the cancer drug
program outside Japan  urn:newsml:reuters.com:*:nBw8xZWZFa
    ** Kyowa Kirin to continue drug trials, explore potential
for submission to Japanese health authorities
    ** As of last close, MEI Pharma shares down 85.4% YTD
 (Reporting by Nandhini Srinivasan in Bengaluru)
 ((nandhini.srinivasan@thomsonreuters.com))